🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Review for @Psychopharm. When you click the "agree to review" link a PDF of the manuscript is automatically dowloaded AND they send you a calendar invite for when the review is due. Every journal should do this for reviewers.

Does a fixed dose of oral THC affect men and women differently? Our new paper in @Psychopharm finds significant sex differences in acute subjective psychoactive effects, but not others. Read more: doi.org/10.1007/s00213… #CannabisResearch #Psychopharmacology Yale Psychiatry

Our @Psychopharm Special Issue on Stress, Trauma, and Cannabinoids from the #EBPS2023 meeting is accepting submissions! First deadline is Sept 1, 2024 ⌛️ Reach out to myself or any of the other editors for questions: connorhaggarty.bsky.social, Christine Rabinak @CBaunez

Out now in @Psychopharm "Reinforcing effects of fentanyl analogs found in illicit drug markets" doi.org/10.1007/s00213…

New paper in @Psychopharm: “Heterogeneity in choice models of addiction: the role of context” with fantastic team Justin Strickland @field_matt @kirstenelins Thrilled about this one. A thread below, but please go read it as well! rdcu.be/dNwnm

As a society, we are keen to promote the development of ECRs. With that in mind, we have a new blog series with papers of interest from our partner journal @Psychopharm Our first posts are on the new page, provided by me (connorhaggarty.bsky.social) & Bart Cooley ebps.org/early-career-r…

I started an “interesting papers” blog over at the Eur Behav Pharm Soc. website with papers from @Psychopharm . Any interested students/postdocs/Asst Profs interested should contact me 😊 It is very likely this will develop over time so any other topics of interest let me know.

Klaus Miczek was a giant of Psychopharmacology: the field and the journal. R.I.P. Here's an interview from 2022. He covers his transformative impact on the journal, evolution of the field, @Psychopharm v Neuropsychopharmacology, writing/editing success, & more. youtu.be/PlUUZ8olWEY?si…

Happy that this manuscript - "The effect of corticosterone on the acquisition of Pavlovian conditioned approach behavior in rats is dependent on sex and vendor" - is now out in Hormones and Behavior. Open access article here... authors.elsevier.com/sd/article/S00… and summary 🧵 below...

CONGRATULATIONS to our class of 2024 Travel Awardees 🥳 #EBPS2024 These 18 recipients will be joining us in Banff and presenting a data blitz on day 1 of the workshop. There is still time to sign up to attend before the September 9th deadline ebps.org.azuleon.org.

Check out our new paper in @Psychopharm on changes in cognition & dopamine systems, and lack thereof, after adolescent THC in rats! Congrats Maricela Martinez, W key support from Stan Floresco!

🚨The UCLA Psychology Department is hiring!!! 🚨 The UCLA Psych department is recruiting a tenure-track Assistant, Associate, or Full Professor in Computational and Behavioral Neuroscience. More info here: recruit.apo.ucla.edu/JPF09740) Applications are open now through October 31 🎃

Today is the first day of #EBPS2024 in beautiful Banff, Alberta! Excited to see a full day of talks on psychedelics, ketamine, hot topics, posters, and more!

Paper of the week: Our new @Psychopharm paper, led by Jennifer Bossert, on the effect of nociceptin receptor partial agonist & antagonist on heroin relapse in our rat model of opioid maintenance. Neither drug mimicked buprenorphine effect in the model pubmed.ncbi.nlm.nih.gov/39269500/

Paper 1 from our special issue "Stress, Trauma and Cannabinoids" in @Psychopharm is out now 😍 (Christine Rabinak, Leah Mayo, @CBaunez)

Cool new paper from the @Psychopharm Eur Behav Pharm Soc. special issue showing presence of the C385A rs324420 polymorphism in the FAAH gene and higher levels of Anandamide are associated with greater PTSD severity in adolescents link.springer.com/article/10.100…

Happy to share Bryan W Jenkins 🧠 latest work published in @Psychopharm: Cannabidiol (CBD) potentiates physiological and behavioral markers of hypothalamic–pituitary–adrenal (HPA) axis responsivity in female and male mice link.springer.com/article/10.100… Amy Newman (she/her) The Lab of NODD collab

Special issue of the month: Excellent @Psychopharm issue on social behavior & neuropsychiatric disorders (editors: Daniele Caprioli, Marco Venniro, Sam Golden & Christelle Baunez). This issue is based on the 2022 EBPS workshop dedicated to this topic pubmed.ncbi.nlm.nih.gov/39969568/

and may I add that this is not a mere "delay" as many institutions are TERMINATING these otherwise active grants if the NoA is delayed by more than 30 days because they cannot afford to keep grant supported research personnel on payroll